Scottsmyname, I will only clarify that IMO there will not be any phase 3 in Multiple system atrophy because MSA is an orphan disease and ATH434 has been granted an orphan status in the USA and EU. With orphan status, a drug can get to the market after positive results in phase 2. IMO, when Stamler has been talking about phase 3, he is talking about a phase 3 study for PD, even though he has not directly told so. It would be stupid to do a phase 3 study on MSA patients but very clever after the successful ape study to do a phase 3 study on PD patients. But of course, the side effects in phase 2 need to be close to the same level as in the placebo group.
Ann: Notice Under Section 708A, page-24
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $570 | 149.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 13513113 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130775819 | 29 |
View Market Depth
| Last trade - 15.46pm 27/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |